Evaluation of safety and efficacy as an adjuvant for the chitosan-based vaccine delivery vehicle ViscoGel in a single-blind randomised Phase I/IIa clinical trial

Vaccine

Volumn 32, Issue 45, 2014, Pages 5967-5974

  Neimert Andersson, Theresa ^a,b   Binnmyr, Jonas ^a,b   Enoksson, Mattias ^a   Langebäck, Joakim ^a   Zettergren, Louise ^a   Hällgren, Anne Charlotte ^a   Franzén, Henry ^a   Lind Enoksson, Sara ^a,b   Lafolie, Pierre ^b   Lindberg, Alf ^b   Al Tawil, Nabil ^c   Andersson, Mats ^a   Singer, Peter ^a   Grönlund, Hans ^b   Gafvelin, Guro ^a,b  

^a Viscogel AB   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Adjuvant; Chitosan; Clinical trial; Haemophilus influenzae type B; Vaccine

Indexed keywords

GAMMA INTERFERON; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; POLY(ETHYL METHACRYLATE); ACT-HIB VACCINE; BACTERIUM ANTIBODY; CHITOSAN; HAEMOPHILUS VACCINE; HYDROGEL; IFNG PROTEIN, HUMAN; IMMUNOLOGICAL ADJUVANT; VACCINE;

ADULT; ANTIBODY PRODUCTION; ANTIBODY TITER; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; HAEMOPHILUS INFLUENZAE TYPE B; HEADACHE; HUMAN; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SINGLE BLIND PROCEDURE; VACCINATION; ADVERSE EFFECTS; BLOOD; CELLULAR IMMUNITY; CHEMISTRY; CLINICAL TRIAL; HAEMOPHILUS INFECTIONS; HYDROGEL; IMMUNOLOGY; MIDDLE AGED; PHARMACOLOGY; YOUNG ADULT;

ADJUVANTS, IMMUNOLOGIC; ADULT; ANTIBODIES, BACTERIAL; CHITOSAN; FEMALE; HAEMOPHILUS INFECTIONS; HAEMOPHILUS VACCINES; HUMANS; HYDROGELS; IMMUNITY, CELLULAR; INTERFERON-GAMMA; MALE; MIDDLE AGED; SINGLE-BLIND METHOD; VACCINES, CONJUGATE; YOUNG ADULT;

EID: 84908006515     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.08.057     Document Type: Article

References (30)

1. Moyle P.M., Toth I. Modern subunit vaccines: development, components, and research opportunities. ChemMedChem 2013, 8:360-376.
2. Garcon N., Segal L., Tavares F., Van Mechelen M. The safety evaluation of adjuvants during vaccine development: the AS04 experience. Vaccine 2011, 29:4453-4459.
3. Schijns V.E., Lavelle E.C. Trends in vaccine adjuvants. Expert Rev Vaccines 2011, 10:539-550.
4. Mbow M.L., De Gregorio E., Valiante N.M., Rappuoli R. New adjuvants for human vaccines. Curr Opin Immunol 2010, 22:411-416.
5. Rappuoli R., Mandl C.W., Black S., De Gregorio E. Vaccines for the twenty-first century society. Nat Rev Immunol 2011, 11:865-872.
6. Reed S.G., Orr M.T., Fox C.B. Key roles of adjuvants in modern vaccines. Nat Med 2013, 19:1597-1608.
7. Neimert-Andersson T., Hallgren A.C., Andersson M., Langeback J., Zettergren L., Nilsen-Nygaard J., et al. Improved immune responses in mice using the novel chitosan adjuvant ViscoGel, with a Haemophilus influenzae type b glycoconjugate vaccine. Vaccine 2011, 29:8965-8973.
8. Gafvelin G., Grönlund H. Chitosan-based adjuvants. Molecular vaccines 2013, Springer International Publishing, Switzerland. M. Giese (Ed.).
9. Mills K.H., Cosgrove C., McNeela E.A., Sexton A., Giemza R., Jabbal-Gill I., et al. Protective levels of diphtheria-neutralizing antibody induced in healthy volunteers by unilateral priming-boosting intranasal immunization associated with restricted ipsilateral mucosal secretory immunoglobulin a. Infect Immun 2003, 71:726-732.
10. McNeela E.A., Jabbal-Gill I., Illum L., Pizza M., Rappuoli R., Podda A., et al. Intranasal immunization with genetically detoxified diphtheria toxin induces T cell responses in humans: enhancement of Th2 responses and toxin-neutralizing antibodies by formulation with chitosan. Vaccine 2004, 22:909-914.
11. Huo Z., Sinha R., McNeela E.A., Borrow R., Giemza R., Cosgrove C., et al. Induction of protective serum meningococcal bactericidal and diphtheria-neutralizing antibodies and mucosal immunoglobulin A in volunteers by nasal insufflations of the Neisseria meningitidis serogroup C polysaccharide-CRM197 conjugate vaccine mixed with chitosan. Infect Immun 2005, 73:8256-8265.
12. Read R.C., Naylor S.C., Potter C.W., Bond J., Jabbal-Gill I., Fisher A., et al. Effective nasal influenza vaccine delivery using chitosan. Vaccine 2005, 23:4367-4374.
13. El-Kamary S.S., Pasetti M.F., Mendelman P.M., Frey S.E., Bernstein D.I., Treanor J.J., et al. Adjuvanted intranasal Norwalk virus-like particle vaccine elicits antibodies and antibody-secreting cells that express homing receptors for mucosal and peripheral lymphoid tissues. J Infect Dis 2010, 202:1649-1658.
14. Atmar R.L., Bernstein D.I., Harro C.D., Al-Ibrahim M.S., Chen W.H., Ferreira J., et al. Norovirus vaccine against experimental human Norwalk Virus illness. N Engl J Med 2011, 365:2178-2187.
15. Zaharoff D.A., Rogers C.J., Hance K.W., Schlom J., Greiner J.W. Chitosan solution enhances both humoral and cell-mediated immune responses to subcutaneous vaccination. Vaccine 2007, 25:2085-2094.
16. Fernandez J., Levine O.S., Sanchez J., Balter S., LaClaire L., Feris J., et al. Prevention of Haemophilus influenzae type b colonization by vaccination: correlation with serum anti-capsular IgG concentration. J Infect Dis 2000, 182:1553-1556.
17. Hallander H.O., Lepp T., Ljungman M., Netterlid E., Andersson M. Do we need a booster of Hib vaccine after primary vaccination? A study on anti-Hib seroprevalence in Sweden 5 and 15 years after the introduction of universal Hib vaccination related to notifications of invasive disease. APMIS 2010, 118:878-887.
18. de Voer R.M., van der Klis F.R., Nooitgedagt J.E., Versteegh F.G., van Huisseling J.C., van Rooijen D.M., et al. Seroprevalence and placental transportation of maternal antibodies specific for Neisseria meningitidis serogroup C, Haemophilus influenzae type B, diphtheria, tetanus, and pertussis. Clin Infect Dis: An Off Publ Infect Dis Soc Am 2009, 49:58-64.
19. Mawas F., Peyre M., Beignon A.S., Frost L., Del Giudice G., Rappuoli R., et al. Successful induction of protective antibody responses against Haemophilus influenzae type b and diphtheria after transcutaneous immunization with the glycoconjugate polyribosyl ribitol phosphate-cross-reacting material 197 vaccine. J Infect Dis 2004, 190:1177-1182.
20. Takala A.K., Eskola J., Leinonen M., Kayhty H., Nissinen A., Pekkanen E., et al. Reduction of oropharyngeal carriage of Haemophilus influenzae type b (Hib) in children immunized with an Hib conjugate vaccine. J Infect Dis 1991, 164:982-986.
21. Kanra G., Viviani S., Yurdakok K., Ozmert E., Anemona A., Yalcin S., et al. Effect of aluminum adjuvants on safety and immunogenicity of Haemophilus influenzae type b-CRM197 conjugate vaccine. Pediatr Int: Off J Jpn Pediatr Soc 2003, 45:314-318.
22. McElhaney J.E., Xie D., Hager W.D., Barry M.B., Wang Y., Kleppinger A., et al. T cell responses are better correlates of vaccine protection in the elderly. J Immunol 2006, 176:6333-6339.
23. Lousada-Dietrich S., Jogdand P.S., Jepsen S., Pinto V.V., Ditlev S.B., Christiansen M., et al. A synthetic TLR4 agonist formulated in an emulsion enhances humoral and Type 1 cellular immune responses against GMZ2 - a GLURP-MSP3 fusion protein malaria vaccine candidate. Vaccine 2011, 29:3284-3292.
24. Streeck H., Frahm N., Walker B.D. The role of IFN-gamma Elispot assay in HIV vaccine research. Nat Protoc 2009, 4:461-469.
25. Saade F., Gorski S.A., Petrovsky N. Pushing the frontiers of T-cell vaccines: accurate measurement of human T-cell responses. Expert Rev Vaccines 2012, 11:1459-1470.
26. Schneerson R., Barrera O., Sutton A., Robbins J.B. Preparation, characterization, and immunogenicity of Haemophilus influenzae type b polysaccharide-protein conjugates. J Exp Med 1980, 152:361-376.
27. Berti F., Adamo R. Recent mechanistic insights on glycoconjugate vaccines and future perspectives. ACS Chem Biol 2013, 8:1653-1663.
28. Avci F.Y., Li X., Tsuji M., Kasper D.L. A mechanism for glycoconjugate vaccine activation of the adaptive immune system and its implications for vaccine design. Nat Med 2011, 17:1602-1609.
29. Sun G., Zhang X., Shen Y.I., Sebastian R., Dickinson L.E., Fox-Talbot K., et al. Dextran hydrogel scaffolds enhance angiogenic responses and promote complete skin regeneration during burn wound healing. Proc Natl Acad Sci USA 2011, 108:20976-20981.
30. Johnson T.D., Christman K.L. Injectable hydrogel therapies and their delivery strategies for treating myocardial infarction. Expert Opin Drug Deliv 2013, 10:59-72.